Abstract
Several studies attempted to identify prognostic factors to predict long-term outcomes and support adjuvant chemotherapy (ACh) after neoadjuvant chemoradiation (NACRT) in rectal cancer. Currently, there is no definitive evidence that ACh is able to improve disease-free survival (DFS). We aimed to evaluate the impact of ACh in DFS in pathological node-negative (ypN0) rectal cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
